...
首页> 外文期刊>BMC Infectious Diseases >Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD)
【24h】

Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD)

机译:澳大利亚艾滋病毒观察数据库(AHOD)中原住民参与者的抗逆转录病毒治疗的使用,合并症和临床结果

获取原文
           

摘要

There are few data regarding clinical care and outcomes of Indigenous Australians living with HIV and it is unknown if these differ from non-Indigenous HIV-positive Australians. AHOD commenced enrolment in 1999 and is a prospective cohort of HIV-positive participants attending HIV outpatient services throughout Australia, of which 20 (74?%) sites report Indigenous status. Data were collected up until March 2013 and compared between Indigenous and non-Indigenous participants. Person-year methods were used to compare death rates, rates of loss to follow-up and rates of laboratory testing during follow-up between Indigenous and non-Indigenous participants. Factors associated with time to first combination antiretroviral therapy (cART) regimen change were assessed using Kaplan Meier and Cox Proportional hazards methods. Forty-two of 2197 (1.9?%) participants were Indigenous. Follow-up amongst Indigenous and non-Indigenous participants was 332 & 16270 person-years, respectively. HIV virological suppression was achieved in similar proportions of Indigenous and non-Indigenous participants 2?years after initiation of cART (81.0?% vs 76.5?%, p?=?0.635). Indigenous status was not independently associated with shorter time to change from first- to second-line cART (aHR 0.95, 95?% CI 0.51-1.76,p?=?0.957). Compared with non-Indigenous participants, Indigenous participants had significantly less frequent laboratory monitoring of CD4 count (rate:2.76 tests/year vs 2.97 tests/year, p?=?0.025) and HIV viral load (rate:2.53 tests/year vs 2.93 tests/year,p?
机译:关于澳大利亚感染艾滋病毒的澳大利亚土著人的临床护理和结果的数据很少,这些数据是否与非艾滋病毒阳性的澳大利亚人不同尚不清楚。 AHOD于1999年开始招募,是整个澳大利亚参加HIV门诊服务的HIV阳性参与者的预期队列,其中20个(74%)站点报告土著身份。收集了截至2013年3月的数据,并对土著和非土著参与者进行了比较。使用人年法比较了土著和非土著参与者的死亡率,随访失访率和实验室检查率。使用Kaplan Meier和Cox比例危害方法评估与首次联合抗逆转录病毒疗法(cART)方案变更时间相关的因素。 2197名参与者中有42名(1.9%)是土著居民。土著和非土著参与者的随访分别为332和16270人年。在启动cART 2年后,土著和非土著参与者的HIV病毒抑制率相似(81.0%对76.5%,p = 0.635)。土著状态与从一线cART转换到二线cART的时间较短并不独立相关(aHR 0.95,95%CI 0.51-1.76,p?= 0.957)。与非土著参与者相比,土著参与者的实验室监测CD4计数(比率:2.76测试/年vs 2.97检查/年,p?=?0.025)和HIV病毒载量(比率:2.53测试/年vs 2.93)的频率明显降低。每年的血脂和血糖测试率几乎是非本地参与者的一半(比率:0.43 /年vs 0.71的测试/年,p?<?0.001)。失访率(23.8%vs 29.8%,p = 0.496)和死亡(2.4%vs 7.1%,p = 0.361)分别发生在土著和非土著参与者中。 ,尽管两组的死因大多与艾滋病毒无关。据我们所知,这是比较土著和非土著HIV阳性澳大利亚人临床结果的第一批数据。在曾经被诊断出感染了艾滋病毒的所有澳大利亚土著居民中,这42名土著参与者占了10%以上。尽管结局没有显着差异,但土著患者的HIV和脂质/葡萄糖参数实验室检测率较低。鉴于普通土著社区患心血管疾病的风险较高,因此,HIV感染的其他危险因素值得进一步关注可改变的危险因素,以使该人群的预期寿命最大化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号